Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX opened at $0.52 on Friday. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The company has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.57. The firm has a market capitalization of $30.59 million, a PE ratio of -0.23 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.